Clinical trials: Non-myeloid Malignancies
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03301168
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bellicum Pharmaceuticals
Cancer Survivor, Chronic Myeloproliferative Disorders
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT01077440
- Testing
- DNA analysis, polymerase chain reaction, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Chronic Myeloid Leukemia
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
This was a non-interventional observational study within the routine chronic myeloid leukemia treatment practice; no further tests were required apart from the assessments routinely performed for Chronic myeloid leukemia patients…
- Trial name
- NOFRETETE (NCT05734053)
- Testing
- Nilotinib
- Where
- 77 sites in Germany
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
The purpose of this study is to compare the efficacy of darbepoetin alfa administered using a front-loading approach with subjects receiving standard weekly dosing in the treatment of anemia in subjects with a non-myeloid…
- Trial name
- NCT00117624
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS)
Biology Studies of Hematologic Cancers
This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Non-Hodgkins Lymphoma, Acute Myelogenous Leukemia
- Trial name
- NCT00923442
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- National Cancer Institute (NCI)
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Acute Myeloid Leukemia, Elderly
Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice
Prospective multicenter, open-lab el, observational, single arm study of decitabine. Subjects will be elderly patients with newly diagnosed, treatment-naïve AML who are unfit to receive and not candidate for intensive induction…
- Conditions
- Acute Myeloid Leukemia, Elderly, Intensive Chemotherapy Unfit
- Trial name
- PURPLE-D (NCT02698124)
- Testing
- Decitabine
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Ulsan University Hospital
Lung Cancer (Diagnosis), Sarcoidosis
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
- Conditions
- Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease, Immunotherapy Resistance
- Trial name
- IMMUNOPUMON2 (NCT07384897)
- Testing
- Peripheral Blood Collection for Immune Profiling
- Where
- Belgium
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease
- Trial name
- NCT01158118
- Testing
- Sargramostim, Plerixafor
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Hematologic Malignancies
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
This phase I trial studies the side effects and best dose of targeted marrow irradiation when given with fludarabine phosphate and busulfan before donor progenitor cell transplant in treating patients with hematologic…
- Conditions
- Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT02129582
- Testing
- total marrow irradiation, fludarabine phosphate, busulfan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
This study seeks to examine treatment therapy that will reduced regimen-related toxicity and relapse while promoting rapid immune reconstitution with limited serious graft-versus-host-disease (GVHD) and also improve disease-free…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML)
- Trial name
- NCT02790515
- Testing
- Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Lymphoma
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
This is a phase I dose escalation study of DT2219ARL for the treatment of relapsed or refractory B-lineage leukemia and lymphoma. Patients will receive a single course of DT2219ARL as a 4 hour infusion on days 1, 3, 5, and 8.
- Trial name
- NCT00889408
- Testing
- DT2219ARL
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-hodgkin Lymphoma
- Trial name
- NCT03088709
- Testing
- Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Loyola University
Hematological Malignancies
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the…
- Trial name
- NCT01607892
- Testing
- KPT-330
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Karyopharm Therapeutics Inc
Leukemia, Lymphoma
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00521430
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Neoplasms, Anemia
Anemia in Patients With a Non-Myeloid Malignancy
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Trial name
- NCT00038064
- Testing
- Darbepoetin alfa, rHuEPO
- Volunteers
- 707 people
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie